Catalyst Clinical Research Named to the 2025 Inc. 5000 List

CRO recognized as a fastest-growing company  

WILMINGTON, N.C., Aug. 12, 2025 /PRNewswire/ -- Catalyst Clinical Research joined the 2025 Inc. 5000 list of the nation's fastest-growing private companies. This year Catalyst earned a spot at 3,833 with 98% growth during the past three years. 

"Being named to the Inc. 5000 list—our third major award recognition in 2025—underscores the strength of our strategy and the dedication of our global teams," said Nik Morton, President and CEO of Catalyst Clinical Research. "As we continue to grow, our commitment to a people-first culture and delivering exceptional outcomes for our clients remains unwavering. These achievements reflect the trust our clients place in us and the passion our teams bring to inspiring people to design and deliver better clinical trials." 

"Making the Inc. 5000 is always a remarkable achievement, but earning a spot this year speaks volumes about a company's tenacity and clarity of vision," says Mike Hofman, Editor-in-Chief of Inc. "These businesses have thrived amid rising costs, shifting global dynamics, and constant change. They didn't just weather the storm—they grew through it, and their stories are a powerful reminder that the entrepreneurial spirit is the engine of the U.S. economy."

Founded in 2013, Catalyst has grown from one North Carolina-based office to hundreds of team members around the world. With our rapid growth, Catalyst Clinical Research has maintained a people-first culture, as evidenced by its industry-leading 12-month retention rate of 92% and 96% employee engagement score in the most recent calendar year.  

Complete Inc. 5000 results, including company profiles sorted by industry, region, and other criteria, can be found at Inc.com/inc5000. 

About Catalyst Clinical Research
Catalyst Clinical Research, a contract research organization (CRO), provides highly customizable solutions to the global biopharmaceutical and biotechnology industries through two established, branded solutions: Catalyst Oncology and Catalyst Flex. The company provides full-service oncology CRO offerings with Catalyst Oncology and multi-therapeutic customer- or Catalyst-managed functional services through Catalyst Flex. With more than 1,000 staff and several offices in the United States, Europe, and the Asia-Pacific region, Catalyst's flexible service model is built from more than a decade of listening to customers, devising customer-centric solutions, and helping customers advance their clinical studies by leveraging expert teams and innovative technologies. Visit Catalyst online at CatalystCR.com or follow us on LinkedIn.   

Catalyst is a portfolio company of QHP Capital, a healthcare and life sciences investment firm.   

About Inc.
Inc. is the leading media brand and playbook for the entrepreneurs and business leaders shaping our future. Through its journalism, Inc. aims to inform, educate, and elevate the profile of its community: the risk-takers, the innovators, and the ultra-driven go-getters who are creating the future of business. Inc. is published by Mansueto Ventures LLC, along with fellow leading business publication Fast Company. For more information, visit www.inc.com.

Media Contact:  
Elizabeth Humphrey 
[email protected] 
+1 (984) 459-2090

SOURCE Catalyst Clinical Research